Skip to main content

Table 1 Baseline demographic, transplant-related characteristics, symptom and treatment-related factors of KTR with COVID-19, i.e., non-survivor vs survivor in KTR with COVID-19

From: Risk factors for mortality in kidney transplant recipients with COVID‐19: a single centre experience and case–control study

Baseline Demographics and COVID Related Characteristics Non-survivor (n = 30) Survivor (n = 188) P-value
1st COVID Wave -n = 16
2nd COVID Wave- n = 14
1st COVID Wave -n = 63
2nd COVID Wave -n = 125
Age n = (> 60(60–71) years:[median-64 yr] < 60 yr(14–60)[median -40 yr] (8:22) (15:173) 0.006
Sex (Male: Female) 23:7 146: 42 0.90
Blood Group (% within Blood Grp)    0.04
O 9 (30%) 39(20.74%)  
B 16 (53.33%) 71(37.76%)  
AB 3(10%) 19(10.11%)  
A 2 (6.66%) 59(31.38%)  
Living donor (n = 167) Vs deceased donor (n = 51) 21(70%) vs 9(30%) 146(77.65%) vs 42(22.34%) 0.39
Post-transplant duration Median (months) min–max 48.5(3–220) 54(0–234) 0.47
Interquartile range (25–50-75) (28.25–48.5–97.25) (24–54-86)  
Diabetes 12 (40%) 44 (23.40%) 0.05
Hypertension 28 (93.33%) 172(91.49%) 1
ATG induction 13 (43.33%) 107(56.91%) 0.17
Delayed graft function 2 (6.66%) 9(4.78%) 0.65
History of treatment for acute rejection in last three-month preceding COVID-19 infection 7 (23.33%) 20 (10.63%) 0.06
History of treatment for tuberculosis 4(13.33%) 22(11.70%) 0.76
Recurrent infection and antimicrobial therapy 7(23.33%) 34(18.08%) 0.46
History of hepatitis C infection 2(6.66%) 23(12.23%) 0.54
Baseline serum creatinine(mg/dl) Median min–max 1.45(0.8–7) 1.2(0.4–4.8) 0.002
Interquartile range (1–1.45–1.85) (1–1.2–1.4)  
Creatinine at presentation(mg/dl) Median Min–Max 3.05(0.76 -9.2) 1.3(0.3–7.5) 0.0001
Interquartile range (1.80–3.05–4.12) (1–1.3–1.7)  
Fever 26(86.66%) 160(85.11%) 1
Myalgia 20(66.66%) 130(69.15%) 0.83
Cough 16 (53.33%) 76 (40.42%) 0.23
Dyspnea 14 (46.66%) 48(25.53%) 0.02
Diarrhea 12 (40%) 28 (14.89%) 0.001
Loss of smell/ageusia 0 10(5.31%) 0.36
Community vs Hospital-acquired 28(93.33%) vs 2(6.66%) 181(96.28%) vs 7(3.72%) 0.35
Coinfection at time of COVID-19 9 (30%) 18(9.57%) 0.002
Lymphopenia at admission 13(43.33%) 31(16.49%) 0.001
CT CORAD¥ score of 4 or more 27(90%) 53(28.19%) 0.0001
Received antibiotics 28(93.33%) 139(63.76%) 0.019
Antimetabolite reduced or stopped 27(90%) 161(85.63%) 0.77
CNI stopped 23(76.66%) 38(20.21%) 0.001
Increase in steroids 14(46.66%) 53(28.19%) 0.38
On Going Graft dysfunction 20(66.66%) 35(18.61) 0.0001
Biopsy-proven acute rejection within three-month period of COVID-19 infection 7(23.33%) 10(5.31%) 0.003
Acute kidney Injury 17(56.66%) 29(15.42%) 0.0001
RRT® during COVID in KTR 13(43.33%) 11(5.85%) 0.0001
Oxygen requirements 30(100.0%) 45(23.93%) 0.0001
Intubation and mechanical ventilation 23(76.66.5%) 2(1.06%) 0.0001
Graft loss 3(10%) 7(3.72%) 0.14
Hospitalisation vs home care 27(90%) vs 3 (10%) 108(57.44%) vs 80(42.55%) 0.0001
Recurrent COVID (n = 2) 1(3.33%) 1(0.53% 0.25
  1. ¥ The coronavirus disease 2019 (COVID-19) Reporting and Data System (CO-RADS)
  2. ® RRT- Renal Replacement Therapy